Augmentation Rates with Dopamine Agonists in RLS
The rotigotine transdermal patch (Neupro®) causes clinically relevant augmentation in approximately 1.5-3% of patients, while pramipexole causes augmentation at similar or slightly higher rates, though the 2025 AASM guidelines now recommend against standard use of both agents specifically due to augmentation risk with long-term use 1, 2, 3.
Specific Augmentation Percentages
Rotigotine Transdermal Patch (Neupro®)
- Short-term (6 months): 1.5% clinically relevant augmentation in double-blind placebo-controlled trials 2
- Medium-term (1 year): 2.9% clinically relevant augmentation in open-label trials 2, 4
- Long-term (5 years): 13% total augmentation rate, with only 5% occurring at EMA-approved doses (1-3 mg/24h) and 8% at supratherapeutic doses (4 mg/24h) 3
The overall augmentation rate using Max Planck Institute (MPI) criteria was 8.2% in 6-month trials, but most cases were not clinically relevant 2.
Pramipexole
While the provided evidence does not give exact percentages for pramipexole augmentation rates, the 2025 AASM guidelines suggest against its standard use with moderate certainty of evidence, specifically citing augmentation as a primary concern 1. The guidelines note that augmentation demonstrated "clinically significant results" in pooled estimates from 2 RCTs and 7 observational studies 1.
Clinical Context and Guideline Implications
The 2025 AASM guidelines represent a major shift, now suggesting against standard use of both pramipexole and transdermal rotigotine 1. This recommendation is based on:
- Pramipexole: Conditional recommendation against standard use (moderate certainty of evidence) 1
- Transdermal rotigotine: Conditional recommendation against standard use (low certainty of evidence) 1
Both medications may still be used in patients who prioritize short-term symptom reduction over long-term augmentation risk 1.
Important Caveats
Dose-dependency: Higher rotigotine doses (4 mg/24h, above EMA-approved range) showed higher augmentation rates (8%) compared to approved doses of 1-3 mg/24h (5%) 3. This suggests staying within approved dosing ranges may reduce augmentation risk.
Time pattern: No clear time-dependent pattern for augmentation was detected with rotigotine, and no patients discontinued due to augmentation alone in trials up to 18 months 2.
Detection methodology: Augmentation rates vary based on diagnostic criteria used. The MPI criteria identified 8.2% with any augmentation but only 1.5% with clinically relevant augmentation in controlled trials 2.
Comparative Perspective
While exact head-to-head augmentation data between pramipexole and rotigotine is limited in the provided evidence, both agents carry sufficient augmentation risk that the AASM now recommends gabapentin and pregabalin as first-line treatments instead (strong recommendations, moderate certainty) 1.